Prevents meningococcal meningitis. ANDA 40091, held by Epic Pharma LLC. Sulfadiazine.
As of Nov 16, 2026, ANDA 40091 (Sulfadiazine), held by Epic Pharma LLC, was first approved by FDA on Jul 29, 1994, with 7 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE sulfADIAZINE Tablets, USP are indicated in the following conditions: Chancroid Trachoma Inclusion conjunctivitis Nocardiosis Urinary tract infections (primarily pyelonephritis, pyelitis and cystitis) in the absence of obstructive uropathy or foreign bodies, when these infections are caused by susceptible strains of the following organisms: Esch erichia coli, Klebsiella species, Enterobacter species, Staphylococcus aureus, Proteus mirabilis and P. vulgaris. Sulfadiazine should be used for urinary tract infections only after use of more soluble sulfonamides has been unsuccessful.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 29, 1994 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Sulfadiazine500MG · tablet;oral | Sulfadiazine | Rx |
| Sep 20, 2002 | Supplement 8Labeling | Approved | None posted |
| Feb 2, 2000 | Supplement 7Manufacturing | Approved | None posted |
| Jul 21, 1998 | Supplement 4Manufacturing | Approved | None posted |
| Jul 21, 1998 | Supplement 5Manufacturing | Approved | None posted |
| Jun 17, 1998 | Supplement 6Labeling | Approved | None posted |
| Oct 8, 1996 | Supplement 3Manufacturing | Approved | None posted |
| Jun 9, 1995 | Supplement 1Manufacturing | Approved | None posted |
| Jul 29, 1994 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters